Indicated for the treatment of relapsed and refractory adult patients with multiple myeloma who have received at least two prior treatments, including lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.

Manufacturer – NATCO PHARMA
Specialty – Hematology
Active principle – Pomalidomide